Evidence map›Paper›PMID 29423452›Full record

ArticleHeliyon2017

Improving biosensing activity to carcinoembryonic antigen with orientated single domain antibodies.

Jinny L Liu, Deepa Raghu, George P Anderson, Ellen R Goldman, Joseph A Christodoulides, Marc P Raphael

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jinny L LiuCenter for Biomolecular Science & Engineering, Naval Research Laboratory, Washington, DC 20375, United States.
Deepa RaghuBioReliance, Sigma-Aldrich Corp, 14920 Broschart Road, Rockville, MD 20850, United States.
George P AndersonCenter for Biomolecular Science & Engineering, Naval Research Laboratory, Washington, DC 20375, United States.
Ellen R GoldmanCenter for Biomolecular Science & Engineering, Naval Research Laboratory, Washington, DC 20375, United States.
Joseph A ChristodoulidesMaterials Science and Technology Division, Naval Research Laboratory, Washington, DC 20375, United States.
Marc P RaphaelMaterials Science and Technology Division, Naval Research Laboratory, Washington, DC 20375, United States.
United States Naval Research Laboratory · USBioReliance (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoembryonic antigen (CEA), also referred as CEACAM5, is integral to the adhesion process during cancer invasion and metastasis and is one of the most widely used tumor markers for assisting the diagnosis of cancer recurrence and cancer metastasis. Antibodies against CEA molecules have been developed for detection and diagnostic applications following tumor removal. Single domain antibodies (sdAbs) against CEA isolated from dromedary and llama exhibited high specificity in binding to tumor cells. However, because these CEA sdAbs were not designed to be orientated when conjugated to surface sensors, there is potential for significant improvements in their activity and limit of detection. Herein we modified the CEA sdAbs with two different C-terminal fusions designed to aid with orientation by way of the tail's charge and biotin binding. A fusion which incorporated the C-terminus addition of a positively charged tail (B5-GS3K) improved biosensor sensitivity to CEA while also retaining the sub-nanomolar binding affinity and thermal stability of the unmodified sdAb. Using our fabricated surfaces on bare gold chips and a multiplexed surface plasmon resonance imager (SPRi), we quantified the specific binding activities, defined as the percentage of bound epitopes to the total immobilized, of the sdAb fusions and anti-CEA mAb. Our results demonstrate that monovalent B5-GS3K exhibited significantly improved binding activity, approximately 3-fold higher than bivalent mAb.

Indexed as

BiochemistryBiomedical engineeringOrganic chemistryPharmaceutical science

Identifiers

PMID29423452
PMCPMC5772350
OpenAlexW2773786748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.